School of Gastrointestinal Oncology | Conference

Novel Agents on Horizon for Advanced HCC

April 26th 2016

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.

Immunotherapy Doubts Fading in GI Cancers

April 26th 2016

Immunotherapy approaches are showing early signs of activity against a range of gastrointestinal cancers, defying the skeptical view that these tumors would not respond to the emerging agents succeeding in other malignancies.

Dr. Douglas Evans on Neadjuvant Therapy for Pancreas Cancer

April 26th 2016

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

Multidisciplinary Treatment a Growing Need in Liver Cancer

April 26th 2016

Michael Choti, MD, explains the impact of advancements in the treatment of patients with liver cancer and how building on them will require all oncology professionals to work as a team.

Precision Medicine Vital to Value-Based GI Cancer Care

April 23rd 2016

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

Numerous Frontline CRC Options Allow Individualized Approach

April 23rd 2016

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

Dr. Bekaii-Saab on Active Agents for the Treatment of Colorectal Cancer

April 23rd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Treating GI Cancers Is a “Team Sport,” Conference Leader Says

April 23rd 2016

John L. Marshall, MD, discusses how the management of patients with gastrointestinal cancers requires a multidisciplinary approach.

Dr. Heery on Advancements in Treatment of Neuroendocrine Tumors

April 23rd 2016

Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.